Guardant Health (GH) EBITDA (2017 - 2026)

Guardant Health has reported EBITDA for 10 years, with the latest figure at -$129.1 million in Q2 2026.

• Quarterly EBITDA fell 21.34% year-over-year to -$129.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$470.3 million (down 2.07% YoY) and the FY2025 annual result came in at -$437.2 million, up 1.43% from the prior year.
• EBITDA eased to -$129.1 million in Q2 2026 per GH's latest filing, from -$121.4 million in the prior quarter.
• Over five years, EBITDA peaked at -$99.0 million in Q3 2025 and troughed at -$197.5 million in Q4 2023.
• A 5-year average of -$124.5 million and a median of -$121.1 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2022 and 2024: EBITDA slumped 48.79% in 2022, then jumped 36.22% in 2024.
• Over 5 years, EBITDA stood at -$146.1 million in 2022, then slumped by 35.17% to -$197.5 million in 2023, then surged by 36.22% to -$126.0 million in 2024, then advanced by 4.1% to -$120.8 million in 2025, then retreated by 6.88% to -$129.1 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$129.1 million, -$121.4 million, and -$120.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.